| zurück | |
| Anhang II |
| Index-Nr. | Internationale chemische Bezeichnung | EG-Nummer | CAS-Nummer | Einstufung | Kennzeichnung | Spezifische Konzentrationsgrenzen, M-Faktoren | Anmerkungen | |||
| Gefahrenklasse, Gefahrenkategorie und Gefahrenkodierung | Kodierung der Gefahrenhinweise | Piktogramm, Kodierung der Signalworte | Kodierung der Gefahrenhinweise | Kodierung der ergänzenden Gefahrenmerkmale | ||||||
| 003-003-00-5 | (2-methylpropyl)lithium; isobutyllithium |
440-620-2 | 920-36-5 | Water-react. 1 Pyr. Liq. 1 Skin Corr. 1a STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 |
H260 H250 H314 H336 H400 H410 |
GHS02 GHS05 GHS07 GHS09 Dgr |
H260 H250 H314 H336 H410 |
EUH014 | ||
| 005-007-00-2 | boric acid; [1] boric acid, crude natural, containing not more than 85 per cent of H3BO3 calculated on the dry weight [2] |
233-139-2 [1] 234-343-4 [2] |
10043-35-3 [1] 11113-50-1 [2] |
Repr. 1B | H360FD | GHS08 Dgr |
H360FD | Repr. 1B; H360FD: C> 5,5 % | ||
| 005-008-00-8 | diboron trioxide; boric oxide |
215-125-8 | 1303-86-2 | Repr. 1B | H360FD | GHS08 Dgr |
H360FD | Repr. 1B; H360FD: C> 3,1 % | ||
| 005-011-00-4 | disodium tetraborate, anhydrous; boric acid, disodium salt; [1] tetraboron disodium heptaoxide, hydrate; [2] orthoboric acid, sodium salt [3] |
215-540-4 [1] 235-541-3 [2] 237-560-2 [3] |
1330-43-4 [1] 12267-73-1 [2] 13840-56-7 [3] |
Repr. 1B | H360FD | GHS08 Dgr |
H360FD | Repr. 1B; H360FD: C> 4,5 % | ||
| 005-011-01-1 | disodium tetraborate decahydrate; borax decahydrate |
215-540-4 | 1303-96-4 | Repr. 1B | H360FD | GHS08 Dgr |
H360FD | Repr. 1B; H360FD: C> 8,5 % | ||
| 005-011-02-9 | disodium tetraborate pentahydrate; borax pentahydrate |
215-540-4 | 12179-04-3 | Repr. 1B | H360FD | GHS08 Dgr |
H360FD | Repr. 1B; H360FD: C> 6,5 % | ||
| 005-013-00-5 | diethylmethoxyborane | 425-380-9 | 7397-46-8 | Pyr. Liq. 1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 4 |
H250 H332 H312 H302 H373** H314 H317 H413 |
GHS02 GHS05 GHS08 GHS07 Dgr |
H250 H332 H312 H302 H373** H314 H317 H413 |
|||
| 005-014-00-0 | 4-formylphenylboronic acid | 438-670-5 | 87199-17-5 | Skin Sens. 1 | H317 | GHS07 Wng |
H317 | |||
| 005-015-00-6 | 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) | 414-380-4 | 140681-55-6 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H302 H318 H317 H412 |
GHS05 GHS07 Dgr |
H302 H318 H317 H412 |
|||
| 005-016-00-1 | tetrabutylammonium butyl tris-(4-tert-butylphenyl)borate | 431-370-5 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
| 005-017-00-7 | sodium perborate; [1] sodium peroxometaborate; [2] sodium peroxoborate; [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm] |
239-172-9 [1] 231-556-4 [2] |
15120-21-5 [1] 7632-04-4 [2] |
Oxid. Sol. 2 Repr. 1B Acute Tox. 4 * STOT SE 3 Eye Dam. 1 |
H272 H360Df H302 H335 H318 |
GHS03 GHS05 GHS08 GHS07 Dgr |
H272 H360Df H302 H335 H318 |
Repr. 1B; H360Df: C> 9 % Repr. 1B; H360D: 6,5 %< C < 9 % Eye Dam. 1; H318: C> 22 % Eye Irrit. 2; H319: 14 %< C < 22 % |
||
| 005-017-01-4 | sodium perborate; [1] sodium peroxometaborate; [2] sodium peroxoborate; [containing> 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm] |
239-172-9 [1] 231-556-4 [2] |
15120-21-5 [1] 7632-04-4 [2] |
Oxid. Sol. 2 Repr. 1B Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Eye Dam. 1 |
H272 H360Df H331 H302 H335 H318 |
GHS03 GHS06 GHS05 GHS08 Dgr |
H272 H360Df H331 H302 H335 H318 |
Repr. 1B; H360Df: C> 9 % Repr. 1B; H360D: 6,5 %< C < 9 % Eye Dam. 1; H318: C> 22 % Eye Irrit. 2; H319: 14 %< C < 22 % |
||
| 005-018-00-2 | perboric acid (H3BO2(O2)), monosodium salt trihydrate; [1] perboric acid, sodium salt, tetrahydrate; [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate; [3] sodium peroxoborate hexahydrate; [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm] |
239-172-9 [1] 234-390-0 [2] 231-556-4 [3] |
13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] |
Repr. 1B STOT SE 3 Eye Dam. 1 |
H360Df H335 H318 |
GHS05 GHS08 GHS07 Dgr |
H360Df H335 H318 |
Repr. 1B; H360 Df: C> 14 % Repr. 1B; H360D: 10 %< C < 14 % Eye Dam. 1; H318: C> 36 % Eye Irrit. 2; H319: 22 %< C < 36 % |
||
| 005-018-01-X |
(Stand: 11.03.2019)
Alle vollständigen Texte in der aktuellen Fassung im Jahresabonnement
Nutzungsgebühr: 90.- € netto (Grundlizenz)
(derzeit ca. 7200 Titel s.Übersicht - keine Unterteilung in Fachbereiche)
Die Zugangskennung wird kurzfristig übermittelt
? Fragen ?
Abonnentenzugang/Volltextversion